Analyst Research
| Report Title | Price |
|---|---|
|
Provider: ValuEngine, Inc.
|
$127.00
|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: Market Edge
|
$10.00
|
|
Provider: S&P Capital IQ – STARS Reports
|
$115.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
Life Technologies Corp Updates On FY 2012 Revenue Guidance; Raises Low End Of Prior FY 2012 EPS Guidance To A Range In Line With Analysts' Estimates
Life Technologies Corp announced that for fiscal 2012, it expects organic revenue growth of approximately 2% over 2011 revenues of $3.7 billion and non-GAAP earnings per share of $3.95-$4.00. According to I/B/E/S Estimates, analysts are expecting the Company to report revenue of $3.78 billion and EPS of $3.95 for fiscal 2012.
Latest Developments for Life Technologies Corp
- Life Technologies Corp Issues Q2 2013 Guidance Below Analysts' Estimates-Conference Call
- Thermo Fisher Scientific Inc To Buy Life Technologies Corp-Reuters
- Life Technologies Corp Acquires KDR Biotech Co., LTD
- Thermo Fisher Scientific Inc Bids For Life Technologies Corp; Blackstone Group LP, Carlyle Group LP And Other PE Firms Finalizing Offer-Reuters
Latest Key Developments in Biotechnology
- Apricus Biosciences Inc Prices $17.1 Million Public Offering Of Common Stock And Warrants
- Stemline Therapeutics Inc Announces Exercise Of Option To Purchase Additional Shares
- Omeros Corp Announces Clearence Of New Drug Application By FDA For OMS824 In Huntington's Disease
- Miraca Holdings Inc Appoints Corporate Auditor
- Share this
- Link this
- Digg this
Follow Reuters